Thrombin-activable fibrinolysis inhibitor (TAFI) is a human plasma zymogen similar to
pancreatic pro-carboxypeptidase B. Cleavage of the zymogen by thrombin/thrombomodulin
generates the enzyme, activated TAFI (TAFIa), which retards fibrin clot lysis in vitro and likely
modulates fibrinolysis in vivo. In the present work we stably expressed recombinant TAFI in
baby hamster kidney cells, purified it to homogeneity from conditioned serum-free medium,
and compared it to plasma TAFI (pTAFI) with respect to glycosylation and kinetics of …